Sawai Group Holdings Co., Ltd.
Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 [IFRS] (Consolidated)
For the third quarter of the fiscal year ending March 2026, revenue was 154,864 million yen (8.1% Year-over-Year increase), operating income was 15,943 million yen (25.7% Year-over-Year decrease), and net income attributable to owners of parent for the quarter was 10,749 million yen (57.8% Year-over-Year decrease).
Key Figures
- Revenue: 154,864 million yen (8.1% Year-over-Year increase)
- Operating Income: 15,943 million yen (25.7% Year-over-Year decrease)
- Net Income Attributable to Owners of Parent for the Quarter: 10,749 million yen (57.8% Year-over-Year decrease)
AI要約
Performance Overview
Consolidated results for the third quarter of the fiscal year ending March 2026 showed revenue of 154,864 million yen (8.1% Year-over-Year increase), while operating income declined to 15,943 million yen (25.7% Year-over-Year decrease) and net income attributable to owners of parent for the quarter decreased to 10,749 million yen (57.8% Year-over-Year decrease). Core operating income reached 23,118 million yen (1.1% Year-over-Year increase), indicating steady profit excluding non-recurring factors. The U.S. business is classified as discontinued operations, and revenue and other figures are presented for continuing operations only.
Financial Position and Cash Flows
Total assets stood at 377,030 million yen, an increase of 22,408 million yen compared to the end of the previous consolidated fiscal year. Total liabilities increased by 17,461 million yen to 198,230 million yen, and total equity increased by 4,946 million yen to 178,800 million yen. Cash and cash equivalents were 46,122 million yen, up 7,336 million yen from the end of the previous year. Cash flow from operating activities was an inflow of 2,846 million yen, investing activities resulted in an outflow of 19,150 million yen, and financing activities provided an inflow of 23,571 million yen.
Business Environment and Future Initiatives
In light of the expanding generic pharmaceutical market and government policies aimed at supply stabilization, the company is advancing its medium-term management plan 'Beyond 2027.' It pursues a multifaceted growth strategy including strengthening quality control, enhancing production capacity, and expanding its digital healthcare business. Earnings per share, adjusted for the stock split in October 2024 (1 share → 3 shares), was 93.09 yen. Full-year earnings guidance forecasts revenue of 202,500 million yen, operating income of 20,900 million yen, and net income attributable to owners of parent of 14,000 million yen.
